working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRK, in red and back to the starting point
will fall
Acquisition example:
"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005314/en/
Acceleron is focused on harnessing the power of the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Sotatercept is in Phase 3 trials as add-on to current standard of care for the treatment of PAH.
“Strategic business development is a top priority for Merck as we look to drive sustainable growth and further bolster and balance our pipeline with breakthrough science,” said Rob Davis, chief executive officer and president, Merck. “Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease.”
In addition to sotatercept, Acceleron’s portfolio includes REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation recombinant fusion protein approved in the United States, Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders. REBLOZYL is being developed and commercialized through a global collaboration with Bristol Myers Squibb..."
MRK -1.4%, shooting star, soon back to origin
well, that's something that I know can happen. but it would be foolish to sell now. what is the game of the detractors but to incite to sell?
because we don't need a "guardian angel"
waiting for the results calmly. The PPS of today or tomorrow is indifferent to me, I will not sell.
a question: if mild and moderate patients are treated and do not get hospitalized, where are we?
$ 0.23 buy while you can, the clock is ticking
the one who has sold, ... begins to regret
0.214985$ last
thank you, buy some here
Today is silly, we will recover ground and wait for the results
what is the problem in that there are several treatments? in fact THERE WILL BE SEVERAL TREATMENTS, there are several vaccines, time to buy more,
what problem exists? there are several vaccines
-15%, 500k volume in 10 minutes,
It seems that we will go to 0.22 and see if 0.20
last 0,26$, and the ASK 0,2598$ Lol
I'm long on IPIX for years, but why should we believe this,
If it were true there would be no way to hide it and we would have multiplied our PPS by 10
last 0.27$ and the ASK 0.25$. LOL
The reaction to the news was: in the first ten minutes 1 million securities traded and 0.27$, in the remaining hours 1 million securities traded and closed at 0.2626$
after the first hour, falls from 0.27 to 0.23 without volume and rapid recovery to 0.26 (manipulation)
I'm not a guesser (you are) we'll see what happens when we get the PII results
poor price action?
low 0.23, high 0.27, close 0.2626
they're clearly trying to slow down, we'll see if they make it again,
it is clearly seen in L2
they're clearly trying to slow down, we'll see if they make it again
well it seems that nothing at all, as always ... hurts
BID 24 x 25.99 ASK
exact, no doubt
OTC no premarket
we are eager to know your answer
0.2329$ -8%
I am not going to sell, but I am sick of seeing it red every day, it is not normal to be waiting for results from a pII
to .05.?
6000 tit in premarket?
and that's how it is from the first day
I hope to have some volume when the closing approaches, let's see
yes, with 14k tit